Year: 2017
Type: review
Study design: Systematic Review
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: American Heart Association, Abbott Laboratories, Amgen, Bristol-Myers Squibb, AstraZeneca, GlaxoSmithKline, Sanofi, Gilead Sciences, Cytokinetics, European Commission, Astellas Pharma, National Institutes of Health, Novartis Pharma, Abbott Vascular, Relypsa, National Heart, Lung, and Blood Institute
Awards: Transition from Risk Factors to Early HF: Prevalence, Pathogenesis, and Phenomics, Molecular Determinants of Hypertensive HFpEF: Genomics, Transcriptomics, and Proteomics, Determinants, Trajectories, and Consequences of Abnormal Cardiac Mechanics, Role of Female Sex and Hormone Status on HFpEF Pathophysiology and Therapy
OpenAlex ID: W2582848829
